Toast, Inc. TOST 深 滬
等待開盤 09-06 09:30:00 美东时间
40.988
-0.122
-0.30%
華盛通- 最 高41.4499
- 今 開41.355
- 成交量 413.40万股
- 最 低 40.39
- 昨 收 41.11
- 總市值 237.32亿
- 52周最高 49.66
- 市盈率 靜 1272.92
- 換手率 0.71%
- 52周最低 26.05
- 委 比 -13.75%
- 總股本 5.79亿
- 歷史最高 69.93
- 量 比 0.54
- 振 幅 2.58%
- 歷史最低 11.91
- 每 手 1
- 風險率 4.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Marriott, Toast, KeyCorp And More On CNBC's 'Final Trades'
Marriott International, which is down around 4% year-to-date, is Jenny Van Leeuwen Harrington's final trade.
08-27 19:01
Par Technology rises after rating upgrade at BTIG
Shares of Par Technology (NYSE:PAR) rose about 2% on Friday after BTIG upgraded the stock to Buy from Neutral, noting that the company's pipeline will comfortably drive over three years of more than 1...
08-16 00:04
Toast, Amazon, Thermo Fisher Scientific And An Industrial Stock On CNBC's 'Final Trades'
Ritholtz Wealth Management CEO Joshua Brown named Toast his final trade after it reported quarterly earnings of 13 cents per share.
08-14 20:14
Price Over Earnings Overview: Toast
Looking into the current session, Toast Inc. (NYSE:TOST) shares are trading at ...
08-09 06:00
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
12 Analysts Have This To Say About Toast
In the preceding three months, 12 analysts have released ratings for Toast (NYS...
08-06 21:02
Toast shares are trading lower following the release of its Q2 financial results.
Toast shares are trading lower following the release of its Q2 financial result...
08-06 20:54
Morgan Stanley Maintains Overweight on Toast, Raises Price Target to $54
Morgan Stanley analyst Josh Baer maintains Toast (NYSE:TOST) with a Overweight and raises the price target from $50 to $54.
08-06 19:51
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
美股大行评级 | 潜在涨幅36%！花旗上调Coinbase目标价升至505美元；摩根大通维持迪士尼"超配"评级，目标价升至138美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从41美元升至46美元；杰富瑞：维持Kiniksa Pharmaceuticals"买入"评级，目标价从45美元升至54美元
07-30 09:36
